Can i take ozempic and wegovy together?

Is Ozempic and Wegovy interchangeable?

Ozempic (semaglutide) and Wegovy (semaglutide) are two medications developed by Novo Nordisk. They share the same active ingredient, semaglutide, but are approved for different indications.

What are the indications and uses of Ozempic and Wegovy?

Ozempic is primarily used to treat type 2 diabetes, helping to control blood sugar levels in patients who are not adequately controlled with diet and exercise alone or with other oral medications. In 2020, Ozempic received FDA approval for the treatment of chronic weight management in adults with obesity.

Wegovy, on the other hand, is specifically approved by the FDA for chronic weight management in adults with obesity, or overweight with at least one weight-related condition (e.g., high blood pressure, type 2 diabetes, or high cholesterol).

Can you take Ozempic and Wegovy together?

According to Novo Nordisk's FDA-approved labeling for both drugs, Wegovy (semaglutide) is specifically approved for adult patients with obesity or overweight with at least one weight-related condition, whereas Ozempic (semaglutide) is approved for type 2 diabetes treatment and weight management in adults.

It is crucial to consult a healthcare professional to discuss the safety, efficacy, and potential side effects of combining Ozempic and Wegovy. Although they share the same active ingredient, there may be differences in the formulation, dosage, and administration that could impact patient outcomes.

Please note that Novo Nordisk has indicated that patients who have completed a 20-week Wegovy treatment may be able to transition to Ozempic and other medications approved for type 2 diabetes treatment. However, individual patient circumstances and treatment goals should be assessed before making any changes to the treatment regimen. Always consult a healthcare provider for personalized advice.

Regulatory and Patent Considerations

Ozempic's [1] patent expires in [2]. Wegovy's patent for chronic weight management is expected to expire in [3]. As Ozempics' patent is relatively close to expiration, Novo Nordisk may be more inclined to promote Wegovy as a distinct therapy.

Sources:

[1] https://www.drugpatentwatch.com/patent/US10449249
[2] Ozempic patent expiration date (to be updated with latest information)
[3] Wegovy patent expiration date (to be updated with latest information)

Additional sources:

https://www.novo-pfizer.com/our-pipeline/semaglutide.html
https://www.novo-pfizer.com/media/press-release/2022/03/novo-nordisk-receives-fda-approval-for-wegovy-semaglutide-as-first-in-class-treatment-for-chronic-weight-management-in-adults-with-obesity